retatrutide 2 months Unrecognizable in Months: Patient Transformation Today, we shared new data

What Patients Typically Notice As GLP 1 signaling increases, food cues and eating patterns often begin to shift in subtle but meaningful ways

Want a Treatment Plan Tailored to Your Needs

Nearly 1 million Part D enrollees took Mounjaro, approved in 2022 for type 2 diabetes, up from 54,000 in 2022

This achievement sets a powerful benchmark for innovators and generics developers, bridging the gap between scientific complexity and regulatory expectations

This triple mechanism distinguishes retatrutide from existing approved therapies such as semaglutide (a GLP-1 receptor agonist) or tirzepatide (a dual GIP/GLP-1 agonist)

Prioritise high-quality protein sources including lean meats, fish, eggs, dairy products, legumes, and plant-based alternatives